PharmaCyte Biotech, Inc.
PMCB · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.08 | 0.71 | 0.10 |
| FCF Yield | -32.77% | -10.59% | -6.67% | -11.38% |
| EV / EBITDA | -0.20 | -89.49 | 2.58 | 11.61 |
| Quality | ||||
| ROIC | -8.38% | -12.42% | -8.88% | -4.88% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.10 | -6.45 | 0.88 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -38.43% | 43.29% | 7.86% | -23.61% |
| Safety | ||||
| Net Debt / EBITDA | -0.49 | -150.35 | 15.76 | 20.15 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -8,628.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |